Americas Healthcare: Biotechnology: EHA Congress Updates

This report details a KOL discussion regarding EHA 2026 data updates for Enliven Therapeutics, Incyte, and Agios Pharmaceuticals. Analysts provide updated views on clinical viability and commercial competitive positioning for these firms.

Key Takeaways

• 1.ELVN-001 showed compelling Ph1 data in CML with potential for 2L+ use and combination with Scemblix.
• 2.INCY's mCALR in myelofibrosis showed durable signals and anemia benefit, though LLY's Ajax drug is viewed as a strong potential competitor.
• 3.AGIO's mitapivat sickle cell Ph3 study missed on VOCs, while NVO's etavopivat is viewed as more convenient due to once-daily dosing.

Table of Contents

• ELVN: Updated Phase 1 data in chronic myeloid leukemia, and commercial positioning amidst NVS' Scemblix and MRK's TERN-701
• INCY: Updated Ph1 data for mCALR program in myelofibrosis and essential thrombocytopenia and the competitive landscape
• AGIO: Full Phase 3 data from mitapivat in sickle cell disease and competitive dynamics with NVO's etavopivat
• Valuation and risks
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial